Human Psychopharmacology-Clinical and Experimental

Papers
(The TQCC of Human Psychopharmacology-Clinical and Experimental is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Issue Information22
Issue Information22
Could improved recognition and treatment of anxiety disorders lead to a reduction in suicide?19
Issue Information14
Issue Information13
‘Nico’—A lone voyager in Strange Seas13
Issue Information13
Lack of psychotropic medication changes among mood disordered women across the peripartum period12
12
Trajectories of sentiment in 11,816 psychoactive narratives12
Elevated serum levels of TNF‐α, IL‐6, and IL‐18 in chronic methamphetamine users12
Factors associated with the severity of delirium11
J Guy Edwards, FRCPsych, FRCP, FRCGP (Hon), DPM, HonMFPH, Founding Editor of Human Psychopharmacology11
Ayahuasca may help to improve self‐compassion and self‐criticism capacities11
The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first‐episode drug‐naive schizophrenic patients10
10
The use of antipsychotics in obsessive compulsive disorder8
Peripheral edema associated with antidepressant use: Systematic review of case reports8
The prevalence of constipation in adult psychiatric out‐patients on clozapine treatment at a regional public hospital in Hong Kong7
Patient outcome following selective serotonin reuptake inhibitor prescribing in primary care in Wales (UK)7
Comparative evaluation of craving, sleep quality, sexual function and quality of life in opioid use disorder patients in remission with buprenorphine/naloxone maintenance treatment7
7
Effect of crocin versus fluoxetine in treatment of mild to moderate obsessive‐compulsive disorder: A double blind randomized clinical trial7
Inverse correlation between plasma 2‐arachidonoylglycerol levels and subjective severity of depression6
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression6
Effect of fasedienol (PH94B) pherine nasal spray and steroidal hormones on electrogram responses and autonomic nervous system activity in healthy adult volunteers5
A diffusion tensor imaging study in schizophrenia patients with clozapine induced obsessive compulsive symptoms5
5
Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis5
5
Efficacy of the nootropic supplement Mind Lab Pro on memory in adults: Double blind, placebo‐controlled study4
Inflammatory markers at baseline correlate with subsequent clinical response to quetiapine in patients with bipolar disorder4
Analysis of schizophrenia‐associated genetic markers in the HLA region as risk factors for tardive dyskinesia4
An explorative approach to understanding individual differences in driving performance and neurocognition in long‐term benzodiazepine users4
5‐MeO‐DMT has not been found in traditional ayahuasca preparations and the combination of 5‐MeO‐DMT with MAOIs is dangerous3
Childhood maltreatment and clinical response to mood stabilizers in patients with bipolar disorder3
Initiation of psychotropic medication in hospitalized patients with COVID‐19: Association with clinical and biological characteristics3
Co‐ingestion of prescription drugs and alcohol in US adults aged 50 years or older3
Comparison of naltrexone implant and oral buprenorphine‐naloxone in the treatment of opiate use disorder3
3
3
2
Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma‐aminobutyric acid–benzodiazepine receptor agonists or suvorexant2
2
Aroma of the essential oil of peppermint reduces aggressive driving behaviour in healthy adults2
Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4‐methylenedioxymethamphetamine users2
Corrigendum2
Issue Information2
Hypothalamic‐pituitary‐adrenal and autonomic response to psychological stress in abstinent alcohol use disorder individuals with and without depressive symptomatology2
Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder2
Antipsychotic‐Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia‐Related Obesity2
A Naturalistic Examination of the Acute Effects of High‐Potency Cannabis on Emotion Regulation Among Young Adults: A Pilot Study2
2
Experience and views of healthcare professionals towards people who use new psychoactive substances: Evidence from statutory, non‐statutory, and private mental health and addiction healthcare services2
Lithium in bipolar depression: A review of the evidence2
Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first‐episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms2
Issue Information2
0.11663293838501